Literature DB >> 17545742

The diagnosis and course of frontotemporal dementia.

Andrew Kertesz1, Mervin Blair, Paul McMonagle, David G Munoz.   

Abstract

The course of frontotemporal dementia (FTD) is examined in a prospective, incipient clinical cohort. Three hundred nineteen patients were followed yearly for an average of 3.6 years. The relative frequencies at presentation were Behavioral variety (FTD-bv) 37.6%, Primary Progressive Aphasia (PPA) 31.6%, possible PPA 10.6%, Corticobasal Syndrome (CBDS) and Progressive Supranuclear Palsy (PSP) 8.1%, Semantic Dementia (SD) 6.6%, and possible FTD 5.3%. The age of onset was significantly lower in the FTD-bv and SD groups than in the rest, but survival and sex distribution was similar in all groups. The evolution is characterized by the appearance of additional FTD syndromes in two-thirds of the patients. A significant association of SD with FTD-bv and CBDS/PSP with PPA was found. The Frontal Behavioral Inventory was highly sensitive and specific for FTD-bv. Visuospatial function was preserved except in CBDS/PSP. The clinical diagnosis showed a positive predictive value of 87% against autopsy in 67 patients. Multiple syndromes increase the likelihood of FTD pathology. In conclusion, the clinical associations follow the tau-negative and tau-positive pathologic dichotomy to some extent, but there is too much overlap to consider the clinical groups or their associations separate diseases.

Entities:  

Mesh:

Year:  2007        PMID: 17545742     DOI: 10.1097/WAD.0b013e31806547eb

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  26 in total

1.  Making sense of progressive non-fluent aphasia: an analysis of conversational speech.

Authors:  Jonathan A Knibb; Anna M Woollams; John R Hodges; Karalyn Patterson
Journal:  Brain       Date:  2009-08-20       Impact factor: 13.501

Review 2.  Extrapyramidal syndromes in frontotemporal degeneration.

Authors:  Andrew Kertesz; Paul McMonagle; Sarah Jesso
Journal:  J Mol Neurosci       Date:  2011-09-02       Impact factor: 3.444

Review 3.  Young-onset dementia epidemiology applied to neuropsychiatry practice.

Authors:  Bhargavi Devineni; Chiadi U Onyike
Journal:  Psychiatr Clin North Am       Date:  2015-03-26

Review 4.  Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Authors:  Gil D Rabinovici; Bruce L Miller
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

5.  Visual search patterns in semantic dementia show paradoxical facilitation of binding processes.

Authors:  Indre V Viskontas; Adam L Boxer; John Fesenko; Alisa Matlin; Hilary W Heuer; Jacob Mirsky; Bruce L Miller
Journal:  Neuropsychologia       Date:  2011-01-06       Impact factor: 3.139

Review 6.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

Review 7.  Language, executive function and social cognition in the diagnosis of frontotemporal dementia syndromes.

Authors:  Michał Harciarek; Stephanie Cosentino
Journal:  Int Rev Psychiatry       Date:  2013-04

Review 8.  [Chronic progressive aphasia].

Authors:  J Diehl-Schmid; C Knels; A Danek
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

9.  Criteria for the diagnosis of corticobasal degeneration.

Authors:  Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner
Journal:  Neurology       Date:  2013-01-29       Impact factor: 9.910

10.  Alzheimer's disease neuropathologic changes in semantic dementia.

Authors:  Tiffany W Chow; Arousiak Varpetian; Taryn Moss; Harry V Vinters; Stefanie Marquez; Carol Miller
Journal:  Neurocase       Date:  2009-10-28       Impact factor: 0.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.